BUZZ-Evercore spots buying opportunity in West Pharma amid strong Oral Wegovy prescription data

Reuters02-03
BUZZ-<a href="https://laohu8.com/S/EVR">Evercore</a> spots buying opportunity in West Pharma amid strong Oral Wegovy prescription data

** Brokerage Evercore ISI says West Pharma's shares WST.N are down about 15% since Novo Nordisk launched oral Wegovy on Jan 5, because investors are worried oral GLP‑1 pills could reduce demand for injectable GLP‑1 drugs, which matter for WST's growth

** Evercore argues the recent selloff creates a good long-term buying opportunity, mainly because WST's core business outside GLP‑1s is improving

** WST's most notable customers include pharma majors Eli Lilly LLY.N and Novo Nordisk NOVOb.CO who incorporate West's components into their blockbuster injectable treatments, particularly in weight-loss and diabetes therapies

** Brokerage believes early prescription strength could be due to a "bolus of needle-phobes" who were waiting specifically for a pill option

** "Pharma remains highly invested in the injectable GLP- category… As just last week Lilly LLY.N announced plans to invest >$3.5 Bn in a new injectable facility" - Evercore ISI

** WST stock was down 16% in 2025

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment